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Antihypertensive medications complicate studies of blood pressure (BP) natural history; BP
if untreated (“underlying BP”) needs to be estimated. Our objectives were to compare valid-
ity of five missing data imputation methods to estimate underlying BP and longitudinal asso-
ciations of underlying BP and age. We simulated BP treatment in untreated hypertensive
participants from Atherosclerosis Risk in Communities (ARIC) in visits 1–5 (1987–2013)
using matched treated hypertensive participants. The underlying BP was imputed: #1, set
as missing; #2, add 10 mmHg for systolic, 5 mmHg for diastolic; #3, add medication class-
specific constant; #4, truncated normal regression; and #5, truncated normal regression
including prior visit data. Longitudinal associations were estimated using linear mixed mod-
els of imputed underlying BP for simulated treated and measured BP for untreated partici-
pants. Method 3 was the best-performing for systolic BP; lowest relative bias (5.3% for
intercept at age 50, 0% for age coefficient) and average deviation from expected (0.04 to
-1.79). Method 2 performed best for diastolic BP; lowest relative bias (0.6% intercept at age
50, 33.3% age <60, 9.1% age 60+) and average deviation (-1.25 to -1.68). Methods 4 and 5
were comparable or slightly inferior. In conclusion, constant addition methods yielded valid
and precise underlying BP and longitudinal associations.
Introduction
Hypertension, systolic blood pressure (SBP)140 mmHg or diastolic blood pressure (DBP)
90 mmHg, is prevalent in the U.S, affecting more than 30% of adults [1–3]. The incidence of
hypertension is rising with lifetime estimates approaching 90% [4,5]. Along with increasing
prevalence, antihypertensive medication use is growing [6,7]. This trend is in part also attrib-
uted to the increase in hypertension awareness [6,7]. Among U.S. adults with hypertension,
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The Atherosclerosis Risk in Communities Study is
the prevalence of antihypertensive medication use has increased from 63.5% in 2001–2 to
77.3% in 2009–10 [6].
Increasing use of antihypertensive medications is certainly important for preventing com-
plications of hypertension but makes studies of blood pressure (BP) natural history difficult to
investigate. For instance, setting BP to missing for all subjects receiving antihypertensive treat-
ment can substantially reduce the sample size and power to detect effects of interest. Alterna-
tively, including treated BP measures while investigating BP natural history can bias results
towards subset of non-hypertensive subjects. In order to prevent these biases, several methods
have been proposed to impute the “underlying BP”, BP that would have been measured if the
individual was not taking antihypertensive medications. Adding a constant BP to the mea-
sured BP of the treated individual has been most commonly used, especially in genetic
epidemiology [8–10]. More recent methodology incorporates regression-based imputation
[8,11,12]. However most of these studies focus on evaluating in cross-sectionally [8,11], and
few have investigated longitudinal settings [12], a time frame more relevant to natural history.
Indeed, multiple BP measurements in longitudinal studies may amplify biases of not account-
ing for treatment. Alternatively, prior BP under no antihypertensive medications in longitudi-
nal settings may be informative to estimate underlying BP in case an individual subsequently
starts taking antihypertensive medications.
Therefore, the objective of this study is to comprehensively compare existing methods to
impute underlying BP among individuals taking antihypertensive medications in a longitudi-
nal setting using data from a large community-based cohort, the Atherosclerosis Risk in Com-
munities (ARIC) Study, with repeated BP measurements over 26 years of follow-up.
Materials and methods
Study population
The ARIC Study recruited 15,792 individuals aged 45–64 years from four communities in
Forsyth County, NC; Jackson, MS; northwest suburbs of Minneapolis, MN; and Washington
County, MD. To date, ARIC has completed the baseline in 1987–89 and four follow-up visits
in 1990–92, 1993–95, 1996–98 and 2011–13, respectively. Detailed study design and methods
have been previously described [13,14]. All visits included interviews, anthropometric mea-
surements, and BP measurements under a common protocol.
BP was measured via a random zero sphygmomanometer in visits 1–4 and an automatic
sphygmomanometer (OMRON HEM-907 XL) in visit 5 by a certified trained technician in
accordance with ARIC manual of procedures [13,15]. Briefly, participants were asked not to
smoke, eat, perform physical exertion or experience cold temperatures 30 minutes prior to
measurements. Participants were also asked to stay in a sitting position for at least 5 minutes
prior to measurements. Each participant contributed three BP measurements per visit for visits
1–3 and 5 and the reported BP was an average of the second and third measurements [13–15].
For visit 4, BP was measured twice and reported as the average [13,14].
For this study, participants with measurements of SBP and DBP at 2 or more visits and
data on antihypertensive medication use and class of medication were included. Other req-
uisite variables were age, sex, race, and body mass index (BMI). Detailed inclusion criteria
for visits 1–5 are presented in S2 Table. The ARIC study has been approved by Institutional
Review Boards (IRB) at all participating institutions: University of North Carolina at Chapel
Hill IRB, Johns Hopkins University IRB, University of Minnesota IRB, and University of
Mississippi Medical Center IRB. Study participants provided written informed consent at
all study visits.
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carried out as a collaborative study supported by
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Simulation study
We generated hypothetical studies where the goal was to evaluate the natural history of under-
lying BP but where some patients were treated for hypertension. The hypothetical study popu-
lation consisted of all non-hypertensive participants (SBP<140 mmHg, DBP <90 mmHg, not
taking antihypertensive medications) and untreated hypertensive participants (not taking anti-
hypertensive medications despite either SBP140 mmHg or DBP90 mmHg) at each visit.
We will refer to the BP among the untreated hypertensive participants as “measured untreated
BP”. Then, we simulated treatment for the untreated hypertensive participants by assigning a
hypothetical treated BP (“simulated treated BP”) as the measured BP from a matched treated
hypertensive participant (taking antihypertensive medications). Matching was performed
using strong predictors of BP, including age ± 5 years, sex, race and BMI ± 5 kg/m2. Using
antihypertensive medication literature to guide us [6–8,10,16,17], we also included in the
matching criteria that the simulated treated BP to be within a conservative interval of 20
mmHg for SBP and 10 mmHg for DBP of the measured untreated BP. If more than one treated
hypertensive subject satisfied the above matching criteria, then one of the subjects that met the
criteria was chosen at random.
We subsequently applied five methods to account for the treatment of the hypertensive
patients within our hypothetical study. First, we set the underlying BP value to missing for all
participants in the hypothetical study that were taking antihypertensive medications (Method
1). The remaining four methods imputed the underlying BP using the simulated treated BP.
Method 2 (simple constant addition) added a constant of 10 mmHg to the simulated treated
SBP and 5 mmHg to the simulated treated DBP [8,10,12] and method 3 (medication class-spe-
cific constant addition) was to add a constant to the simulated treated SBP and DBP depending
on the individuals’ medication class. The constants were derived from a summary report of the
effects of antihypertensive medication classes [16]. For six representative medication classes
[3,16], we applied the following expected treatment effect in mmHg for SBP/DBP as constants:
14.3/10.4 if European American and 6.8/6.6 if African Americans for angiotensin-converting
enzyme (ACE) inhibitors, 15.5/11.7 for alpha blockers, 14.8/12.2 for beta blockers, 15.3/10.5
for calcium channel blockers (including dihydropyridine and non- dihydropyridine), 15.5/9.0
for diuretics (including thiazide-like and loop), and 14.8/10.5 for miscellaneous BP-lowering
medications [16]. Race specific medication constants were used for ACE inhibitors due to the
clear difference by race unlike the other five medication classes (S1 Table) [16]. If the partici-
pant was taking combination therapy, the medication with the largest expected monotherapy
effect was chosen as the primary medication and the non-primary medications had a percent-
age of their monotherapy effect listed above [16]. Detailed description of the estimated treat-
ment effects is provided elsewhere [16], and a summary can be found in S1 Table. For
example, if a participant was taking diuretics and beta blockers, the total expected effect is 17.1
mmHg SBP/13.1 mmHg DBP; the primary medication effect for diuretics is 15.5 mmHg SBP/
9.0 mmHg DBP and the non-primary medication effect for beta-blockers is 1.6 mmHg SBP
(14.8x11%)/4.1 mmHg DBP (12.2x34%).
Methods 4 and 5 imputed the underlying BP using a regression-based approach. Method 4
(truncated normal regression) used a censored normal distribution to generate the imputed
underlying BP by assuming that the distribution of underlying BP is normally distributed and
that the underlying BP is higher than the measured BP under treatment [8]. The censored nor-
mal model was fit using a priori selected predictors of underlying BP from previous literature
[1–3] and empirically included if P<0.05. The SBP model included untreated hypertensive
participants’ age, age2, race, sex, BMI, height, height2, and interaction terms for age and age2
with the sex and height variables. The DBP model included the above variables and instead of
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age2, a spline term for age at 60 years and its respective interaction terms with sex, height, and
height2. Detailed methodology of censored normal regression has been previously published
[8]. Briefly, the underlying BP for a treated participant was imputed by randomly sampling
from a normal distribution with mean defined as the model predicted mean and standard
deviation defined as the model mean squared error where the imputed underlying BP was
greater than the simulated treated BP. This random sampling was repeated 15 times and the
final imputed underlying BP was an average of the 15 values in order to incorporate variability.
Method 5 (truncated normal regression with prior visit BP and antihypertensive treatment)
was the same as method 4 but included two extra predictors, measured BP and the use of anti-
hypertensive medications at the prior visit, in the censored normal regression model.
We simulated 1000 hypothetical studies and applied each of the five methods above to each
simulated study (S1 Fig). As sensitivity analyses, we modified methods 4 and 5 and used 1
instead of 15 repeated sampling of matching in order to incorporate BP variability. All analysis
was performed using R version 3.2.0 [18].
Validity of imputation methods
The validity of the imputation methods was assessed several ways. First, we compared the
distribution of the imputed underlying BP based on methods 2 through 5 to the measured
untreated BP. The average difference between the measured untreated BP and the imputed
underlying BP was calculated for each visit. In addition, we assessed the difference in the
empirical distributions for each of the 1000 simulations using the Anderson-Darling test. The
utility of the Anderson-Darling test may be limited in conditions with large sample size and
deviances from a normal distribution. We interpreted our results within the context of these
limitations.
Subsequently, we obtained the true association between underlying BP and age using the
measured BP values for the hypothetical study population; all non-hypertensive participants
(SBP<140 mmHg, DBP <90 mmHg, not taking antihypertensive medications) and untreated
hypertensive participants; by fitting a linear mixed model including fixed effects for age (spline
at 60 years for DBP, as aforementioned) and random effects at the patient level for both the
intercept (centered at 50 years) and age term(s). The same linear mixed models were fit to the
1000 hypothetical studies applying methods 1 through 5. The relative bias of each method was
defined as the relative difference in the average regression coefficient compared to the true
regression coefficient and was calculated for the model intercept and age term(s).
Our a priori hypothesis was that method 5 would outperform the other methods because
the method was regression-based and incorporated the tracking of prior BP. All analysis was
performed using R version 3.2.0 [18].
Results
Matching and simulation
In brief, 10,283 participants were included in the hypothetical study population, of whom at
visit 1, 9,122 were non-hypertensive and 1,161 were untreated hypertensive and were assigned
simulated treatment. Detailed exclusion criteria (S2 Table) and demographic characteristics of
participants at all other visits (S3–S6 Tables) are provided as supporting information. Results
are primarily presented below using visit 2 since visit 1 was not informative for imputation
methods using prior visit data (method 5) and since results were consistent across the remain-
ing visits with the largest sample size at visit 2.
A total of 1,078 untreated hypertensive participants and 4,720 treated hypertensive partici-
pants had complete data at visit 2 (Fig 1). Table 1 shows the demographic and clinical
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characteristics of 1,078 untreated hypertensive participants compared to the 4,720 treated
hypertensive participants at visit 2. The untreated and treated hypertensive participants were
of comparable age and BMI. In general, the untreated hypertensive participants were more
likely to be male, White and educated at least high school level. Compared to the treated hyper-
tensive participants, comorbid conditions were less prevalent in untreated hypertensive partic-
ipants, including kidney dysfunction (estimated glomerular filtration rate [eGFR] <60 ml/
min/1.73m2), diabetes, prevalent coronary heart disease (CHD), parental history of CHD,
and history of heart failure. All of the untreated hypertensive participants were matched to a
treated hypertensive participant according to the criteria previously described (Fig 1). The dis-
tribution of simulated treated BP was shifted towards lower BP compared to the distribution
of measured untreated BP, as expected (Table 2).
Imputed underlying BP
Table 2 shows the relative accuracy of methods 2 through 5 at imputing the underlying SBP
and DBP (Table 2). In general, the best-performing method was the same for each visit for SBP
and DBP, respectively. Method 3 (class-specific constant addition) was the most accurate for
Fig 1. Matching and imputation scheme for visit 2. At each visit, 14,275 out of 14,348 participants were
included after exclusion for missing age, sex, race, body mass index, antihypertensive medication use and
antihypertensive medication class as well as if they had only 1 visit’s blood pressure (BP). Among the 14,275
participants without missing data, 9,555 participants were not taking antihypertensive medications. 1,078 of
these participants were not taking antihypertensive medications with elevated BP. These untreated
hypertensive participants were matched to one of the treated hypertensive participant (N = 4,720) to
simulated the treated BP.
https://doi.org/10.1371/journal.pone.0179234.g001
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imputing underlying SBP with the mean difference between imputed underlying and underly-
ing SBP ranging from 0.04 at visit 1 to -1.79 at visit 5. Methods 2, 4 and 5 had similar perfor-
mance with the mean difference in imputed underlying and underlying SBP of roughly 5. For
DBP, method 2 had the lowest mean difference in imputed underlying and underlying DBP
across five visits (minimum of -1.25 at visit 1 and maximum of -1.68 at visit 3). After method
Table 1. Summary of participant characteristics at visit 2.
Untreated Hypertensive Participants (N = 1,078) Treated Hypertensive Participants (N = 4,720) P-value
Mean age, yrs (SD) 58.1 (5.8) 58.3 (5.7) 0.47
Male (%) 540 (50.1) 1992 (42.2) <0.01
Race (% Blacks) 333 (30.9) 1697 (36.0) <0.01
Mean BMI*, kg/m2 (SD) 28.7 (5.9) 29.7 (6.0) <0.01
Center (%) <0.01
Forsythe 223 (20.7) 1014 (21.5)
Jackson 290 (26.9) 1500 (31.8)
Minneapolis 327 (30.3) 957 (20.3)
Washington 238 (22.1) 1249 (26.5)
Education less than high school (%) 812 (75.4) 3307 (70.2) <0.01
Current smokers (%) 235 (21.8) 965 (20.5) 0.35
Current drinkers (%) 628 (58.4) 2230 (47.4) <0.01
Kidney dysfunction (%) 20 (1.9) 238 (5.1) <0.01
Diabetes (%) 161 (15.0) 1198 (25.6) <0.01
Prevalent CHD (%) 31 (3.0) 584 (12.6) <0.01
Prevalent heart failure (%) 26 (2.5) 520 (11.2) <0.01
Parental history of CHD* (%) 75 (8.4) 472 (12.4) <0.01
Out of a total of 10,283 participants, untreated hypertensive participants who went through simulation and imputation at visits 1–5 were 1,161, 1,078, 1,012,
1,025, and 333, respectively. Abbreviations: BMI, body mass index; CHD, coronary heart disease; SD, standard deviation.
https://doi.org/10.1371/journal.pone.0179234.t001
Table 2. Accuracy of imputed underlying BP to measured untreated BP.
Method 2 Method 3 Method 4 Method 5
Diff A-D P-value Diff A-D P-value Diff A-D P-value Diff A-D P-value
SBP
Visit 1 5.11 60.70 1.79e-33 0.04 24.80 7.80e-14 6.51 76.70 2.80e-42 6.51 76.70 2.80e-42
Visit 2 4.96 59.20 1.13e-32 0.89 35.70 8.09e-20 6.46 70.90 4.23e-39 5.09 53.10 2.51e-29
Visit 3 5.23 72.80 4.00e-40 1.25 42.80 1.11e-23 6.23 76.90 2.35e-42 4.56 52.70 3.95e-29
Visit 4 4.48 59.50 7.88e-33 -0.19 58.20 3.83e-32 4.95 55.60 1.10e-30 3.54 55.20 1.30e-30
Visit 5 3.91 21.40 5.60e-12 -1.79 16.40 2.92e-9 3.03 14.50 3.32e-8 2.95 12.70 3.36e-7
DBP
Visit 1 -1.25 10.90 3.18e-6 -7.14 109.00 3.14e-60 -1.77 19.90 4.02e-11 -1.77 19.90 4.02e-11
Visit 2 -1.57 11.30 2.04e-6 -6.81 95.70 1.16e-52 -1.93 19.90 3.91e-11 -1.64 12.10 7.26e-7
Visit 3 -1.68 9.21 2.73e-5 -6.99 85.90 2.55e-47 -2.75 26.80 6.26e-15 -2.44 17.20 1.10e-9
Visit 4 -1.67 9.16 2.88e-5 -7.61 101.00 9.08e-56 -3.26 34.80 2.70e-19 -2.83 19.80 4.14e-11
Visit 5 -1.67 2.99 0.03 -8.66 41.10 8.53e-23 -4.08 18.00 4.26e-10 -3.81 13.90 6.96e-8
The mean difference was calculated between the measured untreated BP and the imputed underlying BP. The resulting Anderson-Darling statistic and p-
value estimates the accuracy of imputation methods 2–5. Abbreviations: Diff, difference; A-D, Anderson-Darling test statistic; SBP, systolic blood pressure;
DBP, diastolic blood pressure.
https://doi.org/10.1371/journal.pone.0179234.t002
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2, method 5 followed by methods 4 and 3 had the lowest mean difference between measured
untreated and imputed underlying DBP. The distributions of the imputed underlying BP were
significantly different than the distributions of the measured untreated BP (Table 2), although
the impact of the large sample size on the statistical significance cannot be discounted.
While the mean difference between the imputed underlying and underlying BP gives an
estimate of the average accuracy, the relative accuracy of the imputed underlying BP differed
by the underlying BP. Using one round of SBP imputation at visit 2 as an example (Fig 2), the
imputed underlying SBP tended to underestimate the underlying BP at the outer ranges of the
measured untreated SBP, especially the upper ranges, resulting in V-shaped Bland Altman
plots. This V-shaped pattern was apparent in methods 2–4. The V-shape was partly due to the
matching criteria, which enforced a lower and upper bound in the simulated treated BP, and
partly due to the applicability of each method’s assumptions at the extremes of the simulated
treated BP. The precision of the estimation was also comparable across methods although the
regression-based methods tended to be more precise as expected (Fig 2). Although methods
2–5 demonstrated wide 95% limits of agreement (34.65 to 51.99 mmHg), method 5 (truncated
normal regression with prior visit BP and antihypertensive treatment) yielded the most precise
estimation followed by method 4 (truncated normal regression). The pattern observed for this
Fig 2. Bland-Altman plot of imputed underlying SBP at visit 2. The measured untreated systolic blood
pressure (SBP) was treated as gold standard for the Bland-Altman plots with confidence intervals at 2.5%-
97.5%. Imputed underlying SBP was derived using methods 2–5 (A-D).
https://doi.org/10.1371/journal.pone.0179234.g002
Methods to estimate underlying blood pressure
PLOS ONE | https://doi.org/10.1371/journal.pone.0179234 July 11, 2017 7 / 13
round of imputation for visit 2 was also noted in visits 3–5 and in other rounds of imputation
for both SBP and DBP (S2–S6 Tables).
Longitudinal associations of imputed underlying BP with age
The results of the longitudinal analysis are presented in Table 3 for SBP and DBP. Although
estimations of intercept and age are important for validity, we highlighted the age associations
given the longitudinal nature of our study. The linear association between underlying SBP and
age was underestimated (by 28%) using method 1, where we set the underlying SPB missing
for patients who were treated for hypertension. In comparison, methods 2–4 tended to have
little to no bias (<6%), with lowest bias for method 3. For DBP, the coefficients measuring the
true association between underlying DBP and age were small (0.03 and -0.11 before and after
age 60 years, respectively) and thus even small differences in the average age coefficients across
the imputation methods translated to larger relative bias compared to the SBP analysis. Never-
theless, method 1 yielded the highest bias (200% and 72.7%, respectively). Method 2 yielded
the least biased estimates for both coefficients for age (relative bias 33.3% and 9.1%, respec-
tively). Method 5 also yielded relatively little bias (relative bias 33.3% and 45.5%, respectively).
Discussion
This longitudinal simulation study demonstrated the need for imputation methods to account
for the effect of antihypertensive medications, especially in cohorts drawn from the general
population where medication use is common. As anticipated, setting the treated BP measure-
ments as missing was especially biased. In addition, constant addition methods (methods 2
and 3) tended to be superior to the other methods in both estimating underlying BP and in the
longitudinal analysis of underlying BP and its change over age. Although the truncated normal
regression methods (methods 4 and 5) were comparable, unexpectedly they did not outper-
form methods 2 and 3 overall. Therefore, a hybrid of the method 3 for SBP and method 2 for
DBP may be an option for epidemiological studies focusing on both SBP and DBP.
Our findings are consistent with previous cross-sectional literature. Tobin et al. reported
that the constant addition is better than or equivalent to the truncated normal regression in
cross-sectional setting [8] and surprisingly, we confirmed this in a longitudinal setting. There
Table 3. Bias in intercept and age associations from linear mixed effects models.
Measured Method 1 Method 2 Method 3 Method 4 Method 5
SBP
Intercept Beta (Var) 114.20 116.95 120.60 (5.55e-4) 120.28 (8.25e-4) 120.48 (4.29e-4) 120.62 (3.43e-4)
Relative bias 2.4 5.6 5.3 5.5 5.6
Age Beta (Var) 0.90 0.65 0.85 (8.87e-6) 0.90 (1.36e-5) 0.87 (6.87e-6) 0.88 (6.31e-6)
Relative bias 27.8 5.6 0.0 3.3 2.2
DBP
Intercept Beta (Var) 71.41 69.97 71.85 (7.05e-4) 68.30 (1.52e-2) 71.83 (5.18e-4) 71.79 (1.53e-4)
Relative bias 2.0 0.6 4.4 0.6 0.5
Age before 60 yrs Beta (Var) 0.03 -0.03 0.04 (1.89e-6) 0.07 (3.93e-6) 0.05 (1.00e-6) 0.04 (1.28e-6)
Relative bias 200.0 33.3 133.3 66.7 33.3
Age after 60 yrs Beta (Var) -0.11 -0.19 -0.10 (7.16e-6) -0.03 (3.39e-5) -0.05 (7.16e-6) -0.06 (3.80e-6)
Relative bias 72.7 9.1 72.7 54.6 45.5
The relative bias (%) was calculated as the average relative difference in regression coefficient from each simulation (100 x [βimputation method−βmeasured
untreated BP] / βmeasured untreated BP). Abbreviations: SBP, systolic blood pressure; Var, variance; DBP, diastolic blood pressure.
https://doi.org/10.1371/journal.pone.0179234.t003
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may be several reasons behind the validity of constant addition methods. Firstly since the defi-
nition and management of hypertension are well established, treatment itself and the medica-
tion classes may be more relevant to estimating underlying BP than individual characteristics
such as age and sex. Second, previous work to account for medication use addressed the issue
of underlying BP as a missing data problem [8,11,12,19]. In theory, imputation methods such
as truncated normal regression that are based on variables in the dataset assume that the
dependent variable (i.e. underlying BP) is missing at random (MAR) [8,11,12,19]. However
since underlying BP can be missing not at random (MNAR) or can be due to variables that
were unobserved, not measured well or not included in the model, regression based methods
may not perform as well as expected [8,11,12,19]. This could also contribute to why ignoring
the missingness of underlying BP (method 1) would not be appropriate, as reported previously
[8,11,12,19]. For other traits less variable over time such as cholesterol, regression-based meth-
ods may outperform constant addition methods [20,21]. This may even be true for BP if mea-
sured more often. Nevertheless, constant addition methods are simpler compared to truncated
normal regression and therefore advantageous in the context of large-scale epidemiological
investigations.
Among constant methods, method 3 for SBP and method 2 for DBP performed well. The
discrepancy could be explained in part due to how DBP vs. SBP responds to medication. In
general SBP is well studied since it is a more established risk factor of future cardiovascular dis-
ease and other complications [2,3]. Thus, medications may be investigated for their effect on
SBP more than their effect on DBP. Also just as the relationship between age and DBP is more
complex [2], the relationship between DBP and medication class may be more difficult to sum-
marize as a series of constants. In addition, the range of DBP is smaller than SBP and thus
even slight measurement error in the studies measuring medication effects can be more influ-
ential for DBP. It is also important to note the large relative bias estimates for DBP is in part
due to the small coefficients in the linear mixed models. Finally, we cannot discount that DBP
compared to SBP may be less influenced by the medication class or combination of medica-
tions used for treatment. Thus adding 5mmHg may better capture the effects of antihyperten-
sive medication use for DBP.
This is the first study to our knowledge to comprehensively assess the existing imputation
methods of underlying BP in a longitudinal setting. While our imputation methods relied on
previously published methods [8,12,22], we expanded on these methods by incorporating the
heterogeneity of medication classes in method 3 and the tracking of BP over time in method 5.
Also unlike previous studies, we used data from an existing cohort rather than simulate data
based on a known model [8,12,22]. This allowed for a more empiric assessment of the imputa-
tion methods. Our empiric dataset was robust for addressing antihypertensive use; it was
derived from a large, multi-center cohort with a large proportion of treated and untreated
hypertensive participants. The ARIC cohort also included standard and reliable measurement
of BP and covariates over nearly three decades.
There were some limitations to our study. Firstly, since the number of matches considerably
decreased, we did not take into account comorbid conditions such as kidney dysfunction and
diabetes during matching despite these altering the indication and the effects of antihyperten-
sive medications. For instance, the guidelines for BP target levels are different among individu-
als with and without comorbidities such as diabetes. Among individuals with diabetes, the
SBP target levels are <130–140 mmHg and the DBP target levels are <80 mmHg [23]. None-
theless, the relative performance of the imputation methods was consistent with the main
findings even when we included kidney function and diabetes in the matching criteria as a sen-
sitivity analysis (S7 Table). Secondly, our assessment of BP relied on an average of two mea-
surements on a single day in several years, although in clinical practice hypertension would be
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determined based on BP measurements at multiple occasions over several months. Thirdly, a
constant threshold (SBP140 mmHg or DBP90 mmHg) was used in all five ARIC visits for
the simulation even though ARIC visits occurred from 1987–2013 and thresholds for diagnos-
ing and treating hypertension changed overtime (i.e., 160 mmHg SBP/90 mmHg DBP before
1992–3 and 140/90 mmHg since then) [24,25]. Since a constant cutoff over all visits irrespec-
tive of comorbidities was used, bias may have been introduced in classifying participants
as untreated hypertensive and in the matching process. Finally, the adherence and dose of
antihypertensive medications were not measured. Both factors could lead to heterogeneity in
the effect of antihypertensive medications on BP and could affect the observed longitudinal
associations.
Conclusions
In summary, our longitudinal simulation study demonstrated that imputation methods can
account for treatment in large-scale epidemiological studies of BP natural history. Although
both constant addition methods and regression methods are useful, constant addition methods
may outperform regression methods in estimating and modeling underlying BP, especially
SBP. Further studies are required to assess generalizability and robustness of our findings
accounting for possible modifiers of underlying BP such as dose, adherence, and cause of com-
bination therapy.
Supporting information
S1 Fig. Summary of simulation study: Example participant. The figure illustrates an exam-
ple participant (‘Participant A’) with elevated blood pressure (BP) who does not take antihy-
pertensive medications (untreated hypertensive) and thus was eligible for the simulation
study. Participant A’s BP (systolic blood pressure 153/diastolic blood pressure 93) was mea-
sured without antihypertensive treatment (measured untreated BP). Participant A was
matched to a treated hypertensive participant with similar age, sex, race and body mass index
(Participant X). Participant X’s BP (150/90) was used as the simulated treated BP (BP that
would have been measured for Participant A had he/she been taking antihypertensive medica-
tions). Using the simulated treated BP, the following imputation methods were conducted: #1,
set as missing; #2, single constant addition (systolic BP 10/diastolic BP 5); #3, class-specific
constant addition; #4, truncated normal regression; #5, truncated normal regression with prior
visit BP and antihypertensive treatment.
(TIF)
S2 Fig. Bland-Altman plot of imputed underlying DBP at visit 2. The measured untreated
diastolic blood pressure (DBP) was treated as gold standard for the Bland-Altman plots with
confidence intervals at 2.5%-97.5%. Imputed underlying DBP was derived using methods 2–5
(A-D).
(TIF)
S1 Table. Expected effects of antihypertensive therapy for sitting BP. Adapted from Wu J,
Kraja AT, Oberman A, Lewis CE, Ellison RC, Arnett DK, et al. A summary of the effects of
antihypertensive medications on measured blood pressure. Am J Hypertens 2005 Jul;18
(7):935–942. The expected effect of each medication class was estimated and listed overall
and by race for ACE inhibitors. If the medication was used as part of combination therapy,
the average effects of the non-primary medication were reduced. This weighted effect was
expected to be influenced by whether a diuretic was part of the combination therapy. Abbrevi-
ations: BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; ACE,
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angiotensin-converting enzyme.
(DOCX)
S2 Table. Summary of participants and inclusion criteria at visits 1–5. At each visit, partici-
pants were included in the analysis if they did not have missing age, sex, race, body mass index
(BMI), antihypertensive medication use and antihypertensive medication class. Participants
were further excluded if they had blood pressure (BP) measured at only 1 visit. Of the remain-
ing participants, they were classified according to medication status (treated hypertensive,
untreated) and BP levels among untreated (non-hypertensive, untreated hypertensive).
Untreated hypertensive participants were included in the simulation study if they had at least 1
match among the treated hypertensive according to age, sex, race and BMI.
(DOCX)
S3 Table. Summary of participant characteristics at visit 1. Abbreviations: BMI, body mass
index; CHD, coronary heart disease; SD, standard deviation.
(DOCX)
S4 Table. Summary of participant characteristics at visit 3. Abbreviations: BMI, body mass
index; CHD, coronary heart disease; SD, standard deviation.
(DOCX)
S5 Table. Summary of participant characteristics at visit 4. Abbreviations: BMI, body mass
index; CHD, coronary heart disease; SD, standard deviation.
(DOCX)
S6 Table. Summary of participant characteristics at visit 5. Abbreviations: BMI, body mass
index; CHD, coronary heart disease; SD, standard deviation.
(DOCX)
S7 Table. Accuracy of imputed underlying BP to measured untreated BP matched on diabe-
tes and kidney function. The relative bias (%) was calculated as the average relative difference
in regression coefficient from each simulation (100 x [βimputation method−βmeasured untreated BP] /
βmeasured untreated BP). Controls were matched on diabetes and kidney dysfunction status. Abbre-
viations: SBP, systolic blood pressure; Var, variance; DBP, diastolic blood pressure.
(DOCX)
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